0
0
0
0
1
2
3
$0
Is Quest Diagnostics solid or fragile? The Finex Financial Health Scanner reads DGX's real financial statements and scores its debt, liquidity, margins, cash flow and growth, with the Altman Z-score, the Piotroski F-score and the red flags explained in plain words.
| Revenue (FY2025) | $11.0B |
|---|---|
| Net income | $992.0M |
| Operating margin | 14.1% |
| Net margin | 9.0% |
| Cash and investments | $420.0M |
| Total debt | $5.7B |
| Free cash flow | $872.5M |
| Revenue growth (1 year) | 11.8% |
Data: Nasdaq and Yahoo Finance. Educational, not financial advice.